SEC Form 4 · accession 0001213900-26-069246
Protara Therapeutics, Inc. · TARA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jane Huang
Director
Period of report
Jun 15, 2026
Accepted (ET)
Jun 16, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001359931
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.94 | Jun 15, 2026 | A | 31,000 | A | Jun 15, 2027 | Jun 14, 2036 | Common Stock | 31,000 | 31,000 | D |
Explanation of responses
- F11. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.